Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yuki Habu"'
Autor:
Anju Tsukada, Yuko Okamatsu-Ogura, Emi Futagawa, Yuki Habu, Natsumi Takahashi, Mira Kato-Suzuki, Yuko Kato, Satoshi Ishizuka, Kei Sonoyama, Kazuhiro Kimura
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107239- (2023)
Summary: Beige adipocytes are transiently induced during early postnatal period in mice. Previous studies have suggested that, unlike in adults, the induction is independent of the sympathetic nerve activity; however, the mechanism is yet unknown. He
Externí odkaz:
https://doaj.org/article/21e6d92289df48729e4e1a4daeef3d49
Autor:
Shotaro Kamata, Akihiro Honda, Ryo Ishikawa, Makoto Akahane, Ayane Fujita, Chihiro Kaneko, Saeka Miyawaki, Yuki Habu, Yui Shiiyama, Kie Uchii, Yui Machida, Takuji Oyama, Isao Ishii
Publikováno v:
Antioxidants, Vol 12, Iss 8, p 1523 (2023)
No therapeutic drugs are currently available for nonalcoholic steatohepatitis (NASH) that progresses from nonalcoholic fatty liver via oxidative stress-involved pathways. Three cognate peroxisome proliferator-activated receptor (PPAR) subtypes (PPAR
Externí odkaz:
https://doaj.org/article/0accaf46209a47e383198c9c9eddc003
Autor:
Akihiro Honda, Shotaro Kamata, Makoto Akahane, Yui Machida, Kie Uchii, Yui Shiiyama, Yuki Habu, Saeka Miyawaki, Chihiro Kaneko, Takuji Oyama, Isao Ishii
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 9, p 4726 (2022)
Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists a
Externí odkaz:
https://doaj.org/article/81f5a994fd9540b9af50f73bc322649c